[Midline peripheral T-cell lymphoma--a disease entity recognized anew].
Thirty-one cases of midline peripheral T-cell lymphoma (MPTL), treated during the past two years in our hospital, are reported. All were proven by immunohistochemical stain on frozen section, using a panel of antibodies: IIIC4 (CD5), Leu-2, Leu-3, Leu-4, T,p55, T11, Ia, Ki-1, IL2-R, B1/DAKO-CD22, Kappa, Lambda and IgM. Three cases were also stained with LCA, UCHL-1, MT1, MT2, MB1 and MB2 monoclonal antibodies in paraffin sections, and the results conformed with the frozen-sectionmethod. According to our present and previous reports, it is worthy of note that most of the so-called midline malignant reticuloses (MMR) in the past, including necrotic granulomatosis and malignant granulomatosis, are actually MPTL. In view of MPTL being highly malignant and not very rare in this country, it is emphasized that this disease should be paid more attention and recognized anew. More active treatment should be given to improve the results.
Li
J X
JX
Cancer Institute, Chinese Academy of Medical Sciences, Beijing.
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000032:analysis; D000912:Antibodies, Neoplasm / Q000032:analysis; D003937:Diagnosis, Differential; D005260:Female; D006103:Granuloma, Lethal Midline / Q000175:diagnosis; D006258:Head and Neck Neoplasms / Q000175:diagnosis*; D054747:Histiocytic Sarcoma / Q000175:diagnosis; D006801:Humans; D007150:Immunohistochemistry; D016399:Lymphoma, T-Cell / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm